Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Assets (2019 - 2025)

Lyell Immunopharma's Other Non-Current Assets history spans 7 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 450.35% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, up 450.35%, while the annual FY2024 figure was $1.7 million, 495.07% up from the prior year.
  • Other Non-Current Assets for Q3 2025 was $1.6 million at Lyell Immunopharma, roughly flat from $1.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.7 million in Q4 2024 and bottomed at $279000.0 in Q1 2022.
  • The 5-year median for Other Non-Current Assets is $287000.0 (2024), against an average of $606263.2.
  • The largest annual shift saw Other Non-Current Assets plummeted 40.13% in 2022 before it skyrocketed 495.07% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $466000.0 in 2021, then crashed by 39.91% to $280000.0 in 2022, then increased by 1.43% to $284000.0 in 2023, then surged by 495.07% to $1.7 million in 2024, then decreased by 6.21% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Other Non-Current Assets are $1.6 million (Q3 2025), $1.6 million (Q2 2025), and $1.7 million (Q1 2025).